drugset / Trial / NCT00485576

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

NCT00485576

Phase 2 Completed 21 enrolled Alexion Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindPrevention

Summary

This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.

Timeline

Start
2007-09
Primary completion
2008-09
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 600 mg Intravenous

Indications